Cataract News and Research

Latest Cataract News and Research

Carnosine may help prevent, treat cataracts

Researchers are reporting evidence from tissue culture experiments that the popular dietary supplement carnosine may help to prevent and treat cataracts, a clouding of the lens of the eye that is a leading cause of vision loss worldwide.

15 Jul 2009

Bartering for health care rises

With no health insurance and little money, Gilberto Carrasco, a Reno, Nev., auto mechanic, didn't see much point in getting a physical. At 50, he felt healthy and couldn't afford treatment even if a doctor found a medical problem.

17 Jun 2009

Factors linked to failure of corneal transplants

Certain eye conditions appear to put patients at greater risk for having a failed cornea transplant, according the Cornea Donor Study (CDS), a multi-center clinical trial conducted by the National Eye Institute. The study concludes that patients with glaucoma and patients who had corneal swelling following an earlier cataract surgery were more likely to experience failure of the cornea transplant than were other patients in the study.

11 Jun 2009

Topical bevacizumab therapy effective in treating corneal blood vessels growth that can cause blindness

Researchers at the Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute have concluded that short-term topical bevacizumab therapy reduces the severity of corneal neovascularization (formation of new blood vessels in the cornea that can create impaired vision or vision loss) without local or systemic adverse effects.

15 Apr 2009

Bracelet warns of too much sun exposure

Scientists in Britain have come up with what appears a very sensible idea - a team at Strathclyde University in Scotland have developed an early warning sunburn indicator - it comes in the form of a thin strip which turns pink after too much exposure to ultra-violet light.

15 Apr 2009

Exercise programmes reduce falls in seniors

Exercise programmes are an effective option for preventing falls among older people living in the community.

14 Apr 2009

Columbia University licenses retinal imaging technology to PCAsso Diagnostics

Columbia University Science and Technology Ventures announced that it has signed a worldwide exclusive license agreement with PCAsso Diagnostics, LLC to develop and market a novel imaging technology for diagnosis of vascular leakage disorders of the retina.

13 Apr 2009

Seroquel XR supplemental NDA recommended for approval

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for Seroquel XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

9 Apr 2009

Positive phase 3 uveitis trial results for voclosporin

Isotechnika Inc. has announced that their partner, Lux Biosciences, Inc., reported the results from the three Phase 3 LUMINATE trials investigating voclosporin oral capsule (LUVENIQ or LX211) for the treatment of uveitis.

29 Mar 2009

Sirion Therapeutics sNDA for Durezol to treat uveitis accepted for FDA review

Sirion Therapeutics, Inc. announced today that its supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration (FDA) seeking market approval of Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% to treat endogenous anterior uveitis has been accepted for review.

16 Mar 2009

New implantable lenses put high-tech devices within reach, UT Southwestern eye surgeons say

If you're having trouble reading or sending text messages on your new cell phone, UT Southwestern Medical Center eye surgeons may have a remedy.

3 Mar 2009

Lots of exercise may help prevent vision loss

There's another reason to dust off those running shoes. Vigorous exercise may help prevent vision loss, according to a pair of studies from the U.S. Department of Energy's Lawrence Berkeley National Laboratory.

10 Feb 2009

Abbott to acquire Advanced Medical Optics

Abbott and Advanced Medical Optics (AMO) have announced a definitive agreement for Abbott to acquire AMO for $22 per share in cash, for a total transaction value of approximately $2.8 billion, inclusive of estimated net debt at the time of closing.

12 Jan 2009

New cataract early detection device

A compact fiber-optic probe developed for the space program has now proven valuable for patients in the clinic as the first non-invasive early detection device for cataracts, the leading cause of vision loss worldwide.

8 Jan 2009

People with blindness from cataract are poorer than those with normal sight

A new study conducted in three developing countries-Kenya, the Philippines, and Bangladesh-finds that people with cataract-induced visual impairment are more likely to live in poverty than those with normal sight.

16 Dec 2008

Cases of major eye disease projected to increase among diabetics

Based on projected increases in the prevalence of diabetes, the number of people with diabetes-related retinal disease, with glaucoma and with cataracts is estimated to increase significantly by 2050, according to a report in the December issue of Archives of Ophthalmology.

8 Dec 2008

ISTA Pharmaceuticals announces trial results for topical Xibrom 0.09%

ISTA Pharmaceuticals, Inc. has announced results from the Company's recently completed Phase III clinical program of Xibrom (0.09% bromfenac sodium ophthalmic solution) QD (once-daily).

8 Dec 2008

Surgical options for retinal detachment

Retinal detachment, a condition that afflicts about 10,000 Americans each year, puts an individual at risk for vision loss or blindness.

26 Nov 2008

Study evaluates corneal collagen cross-linking in subjects with progressive keratoconus

Presently keratoconus is treated through eyeglasses, hard contact lenses, and a newer treatment, INTACS plastic rings inserted into the mid layer of the cornea to flatten it, changing the shape and location of the cone.

26 Nov 2008

FDA approves GSK's Promacta (Eltrombopag)

GlaxoSmithKline has announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

20 Nov 2008